Glennon RA, Dukat M, Westkaemper RB (1. 1. 2000.). „Serotonin Receptor Subtypes and Ligands”. American College of Neurophyscopharmacology. Pristupljeno 11. 4. 2008.
Gilliam TC, Freimer NB, Kaufmann CA, Powchik PP, Bassett AS, Bengtsson U, Wasmuth JJ (November 1989). „Deletion mapping of DNA markers to a region of chromosome 5 that cosegregates with schizophrenia”. Genomics5 (4): 940–4. DOI:10.1016/0888-7543(89)90138-9. PMID2591972.
de Almeida J, Mengod G. (2008). „Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment.”. J Neurochem.107 (2): 488–496. DOI:10.1111/j.1471-4159.2008.05649.x. PMID18761712.
Kolassa N, Beller KD, Sanders KH. (1989). „Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil.”. Am J Cardiol.64 (7): 7D–10D. DOI:10.1016/0002-9149(89)90688-7. PMID2569265.
Ootsuka Y, Blessing WW. (2006). „Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits.”. Brain Res.1073-1074: 252–61. DOI:10.1016/j.brainres.2005.12.031. PMID16455061.
Rusyniak DE, Zaretskaia MV, Zaretsky DV, DiMicco JA. (2007). „3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: role and location of 5-hydroxytryptamine 1A receptors.”. J Pharmacol Exp Ther.323 (2): 477–487. DOI:10.1124/jpet.107.126169. PMID17702902.
Yu Y, Ramage AG, Koss MC. (2004). „Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats.”. Eur J Pharmacol.489 (3): 207–213. DOI:10.1016/j.ejphar.2004.03.007. PMID15087245.
Prow MR, Martin KF, Heal DJ (1996). „8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation”. Eur J Pharmacol.317 (1): 21–8. DOI:10.1016/S0014-2999(96)00693-0. PMID8982715.
Cryan JF, Redmond AM, Kelly JP, Leonard BE. (1997). „The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat.”. Eur Neuropsychopharmacol.7 (2): 109–114. DOI:10.1016/S0924-977X(96)00391-4. PMID9169298.
Kennett GA, Dourish CT, Curzon G (1987). „Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression”. Eur J Pharmacol.134 (3): 265–74. DOI:10.1016/0014-2999(87)90357-8. PMID2883013.
Lorens SA, Van de Kar LD. (1987). „Differential effects of serotonin (5-HT1A and 5-HT2) agonists and antagonists on renin and corticosterone secretion”. Neuroendocrinology.45 (4): 305–310. DOI:10.1159/000124754. PMID2952898.
Koenig JI, Gudelsky GA, Meltzer HY. (1987). „Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation”. Eur J Pharmacol.137 (1): 1–8. DOI:10.1016/0014-2999(87)90175-0. PMID2956114.
Pitchot W, Wauthy J, Legros JJ, Ansseau M (March 2004). „Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology14 (2): 151–5. DOI:10.1016/S0924-977X(03)00108-1. PMID15013031.
Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). „A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")”. Neuroscience146 (2): 509–14. DOI:10.1016/j.neuroscience.2007.02.032. PMID17383105.
Pike VW, McCarron JA, Lammerstma AA, Hume SP, Poole K, Grasby PM, Malizia A, Cliffe IA, Fletcher A, Bench CJ (1995). „First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635”. Eur. J. Pharmacol.283 (1–3): R1–3. DOI:10.1016/0014-2999(95)00438-Q. PMID7498295.
Price JC, Kelley DE, Ryan CM, Meltzer CC, Drevets WC, Mathis CA, Mazumdar S, Reynolds CF (2002). „Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study”. Brain Res.927 (1): 97–103. DOI:10.1016/S0006-8993(01)03297-8. PMID11814436.
Burnet PW, Eastwood SL, Harrison PJ (1997). „[3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia”. Neurochem. Int.30 (6): 565–574. DOI:10.1016/S0197-0186(96)00124-6. PMID9152998.
Drago A, Ronchi DD, Serretti A (August 2008). „5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies”. Int. J. Neuropsychopharmacol.11 (5): 701–21. DOI:10.1017/S1461145707008218. PMID18047755.
Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E et al. (2007). „Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression”. J Neural Transm114 (8): 1065–8. DOI:10.1007/s00702-007-0705-9. PMID17401528.
Guiard BP, David DJ, Deltheil T, Chenu F, Le Maître E, Renoir T et al. (2008). „Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype”. Int J Neuropsychopharmacol11 (1): 79–92. DOI:10.1017/S1461145707007857. PMID17559709.
Salim, Kamran; Fenton Tim, Bacha Jamil, Urien-Rodriguez Hector, Bonnert Tim, Skynner Heather A, Watts Emma, Kerby Julie, Heald Anne, Beer Margaret, McAllister George, Guest Paul C (May 2002). „Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation”. J. Biol. Chem.277 (18): 15482–5. DOI:10.1074/jbc.M201539200. PMID11854302.
Gilliam TC, Freimer NB, Kaufmann CA, Powchik PP, Bassett AS, Bengtsson U, Wasmuth JJ (November 1989). „Deletion mapping of DNA markers to a region of chromosome 5 that cosegregates with schizophrenia”. Genomics5 (4): 940–4. DOI:10.1016/0888-7543(89)90138-9. PMID2591972.
de Almeida J, Mengod G. (2008). „Serotonin 1A receptors in human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic interneuron subpopulation: implications for schizophrenia and its treatment.”. J Neurochem.107 (2): 488–496. DOI:10.1111/j.1471-4159.2008.05649.x. PMID18761712.
Dabiré H. (1991). „Central 5-hydroxytryptamine (5-HT) receptors in blood pressure regulation.”. Therapie.46 (6): 421–9. PMID1819150.
Kolassa N, Beller KD, Sanders KH. (1989). „Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil.”. Am J Cardiol.64 (7): 7D–10D. DOI:10.1016/0002-9149(89)90688-7. PMID2569265.
Ootsuka Y, Blessing WW. (2006). „Activation of 5-HT1A receptors in rostral medullary raphé inhibits cutaneous vasoconstriction elicited by cold exposure in rabbits.”. Brain Res.1073-1074: 252–61. DOI:10.1016/j.brainres.2005.12.031. PMID16455061.
Rusyniak DE, Zaretskaia MV, Zaretsky DV, DiMicco JA. (2007). „3,4-Methylenedioxymethamphetamine- and 8-hydroxy-2-di-n-propylamino-tetralin-induced hypothermia: role and location of 5-hydroxytryptamine 1A receptors.”. J Pharmacol Exp Ther.323 (2): 477–487. DOI:10.1124/jpet.107.126169. PMID17702902.
Yu Y, Ramage AG, Koss MC. (2004). „Pharmacological studies of 8-OH-DPAT-induced pupillary dilation in anesthetized rats.”. Eur J Pharmacol.489 (3): 207–213. DOI:10.1016/j.ejphar.2004.03.007. PMID15087245.
Prow MR, Martin KF, Heal DJ (1996). „8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation”. Eur J Pharmacol.317 (1): 21–8. DOI:10.1016/S0014-2999(96)00693-0. PMID8982715.
Cryan JF, Redmond AM, Kelly JP, Leonard BE. (1997). „The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat.”. Eur Neuropsychopharmacol.7 (2): 109–114. DOI:10.1016/S0924-977X(96)00391-4. PMID9169298.
Kennett GA, Dourish CT, Curzon G (1987). „Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression”. Eur J Pharmacol.134 (3): 265–74. DOI:10.1016/0014-2999(87)90357-8. PMID2883013.
Lorens SA, Van de Kar LD. (1987). „Differential effects of serotonin (5-HT1A and 5-HT2) agonists and antagonists on renin and corticosterone secretion”. Neuroendocrinology.45 (4): 305–310. DOI:10.1159/000124754. PMID2952898.
Koenig JI, Gudelsky GA, Meltzer HY. (1987). „Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation”. Eur J Pharmacol.137 (1): 1–8. DOI:10.1016/0014-2999(87)90175-0. PMID2956114.
Pitchot W, Wauthy J, Legros JJ, Ansseau M (March 2004). „Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology14 (2): 151–5. DOI:10.1016/S0924-977X(03)00108-1. PMID15013031.
Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (May 2007). „A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy")”. Neuroscience146 (2): 509–14. DOI:10.1016/j.neuroscience.2007.02.032. PMID17383105.
Pike VW, McCarron JA, Lammerstma AA, Hume SP, Poole K, Grasby PM, Malizia A, Cliffe IA, Fletcher A, Bench CJ (1995). „First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635”. Eur. J. Pharmacol.283 (1–3): R1–3. DOI:10.1016/0014-2999(95)00438-Q. PMID7498295.
Price JC, Kelley DE, Ryan CM, Meltzer CC, Drevets WC, Mathis CA, Mazumdar S, Reynolds CF (2002). „Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study”. Brain Res.927 (1): 97–103. DOI:10.1016/S0006-8993(01)03297-8. PMID11814436.
Burnet PW, Eastwood SL, Harrison PJ (1997). „[3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia”. Neurochem. Int.30 (6): 565–574. DOI:10.1016/S0197-0186(96)00124-6. PMID9152998.
Drago A, Ronchi DD, Serretti A (August 2008). „5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies”. Int. J. Neuropsychopharmacol.11 (5): 701–21. DOI:10.1017/S1461145707008218. PMID18047755.
Anttila S, Huuhka K, Huuhka M, Rontu R, Hurme M, Leinonen E et al. (2007). „Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression”. J Neural Transm114 (8): 1065–8. DOI:10.1007/s00702-007-0705-9. PMID17401528.
Guiard BP, David DJ, Deltheil T, Chenu F, Le Maître E, Renoir T et al. (2008). „Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype”. Int J Neuropsychopharmacol11 (1): 79–92. DOI:10.1017/S1461145707007857. PMID17559709.
Salim, Kamran; Fenton Tim, Bacha Jamil, Urien-Rodriguez Hector, Bonnert Tim, Skynner Heather A, Watts Emma, Kerby Julie, Heald Anne, Beer Margaret, McAllister George, Guest Paul C (May 2002). „Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation”. J. Biol. Chem.277 (18): 15482–5. DOI:10.1074/jbc.M201539200. PMID11854302.
